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Abstract
Background: Since 1985, two antigenically distinct lineages of influenza B viruses (Victoria-like and Yamagata-like)
have circulated globally. Trivalent seasonal influenza vaccines contain two circulating influenza A strains but a single
B strain and thus provide limited immunity against circulating B strains of the lineage not included in the vaccine.
In this study, we describe the characteristics of influenza B viruses that caused respiratory illness in the population
in Italy over 13 consecutive seasons of virological surveillance, and the match between the predominant influenza B
lineage and the vaccine B lineage, in each season.
Methods: From 2004 to 2017, 26,886 laboratory-confirmed influenza cases were registered in Italy, of which 18.7%
were type B. Among them, the lineage of 2465 strains (49%) was retrieved or characterized in this study by a real-
time RT-PCR assay and/or sequencing of the hemagglutinin (HA) gene.
Results: Co-circulation of both B lineages was observed each season, although in different proportions every year.
Overall, viruses of B/Victoria and B/Yamagata lineages caused 53.3 and 46.7% of influenza B infections, respectively.
A higher proportion of infections with both lineages was detected in children, and there was a declining frequency
of B/Victoria detections with age. A mismatch between the vaccine and the predominant influenza B lineage
occurred in eight out of thirteen influenza seasons under study. Considering the seasons when B accounted for >
20% of all laboratory-confirmed influenza cases, a mismatch was observed in four out of six seasons. Phylogenetic
analysis of the HA1 domain confirmed the co-circulation of both lineages and revealed a mixed circulation of
distinct evolutionary viral variants, with different levels of match to the vaccine strains.
Conclusions: This study contributes to the understanding of the circulation of influenza B viruses in Italy. We found
a continuous co-circulation of both B lineages in the period 2004–2017, and determined that children were
particularly vulnerable to Victoria-lineage influenza B virus infections. An influenza B lineage mismatch with the
trivalent vaccine occurred in about two-thirds of cases.
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Background
Influenza A(H1N1), A(H3N2) and influenza B viruses are
responsible for a significant disease burden during seasonal
epidemics in humans [1]. Worldwide, these annual epi-
demics are estimated to cause about 3–5 million cases of
severe illness and 290,000–650,000 deaths [2]. In the past,
influenza B viruses were believed to cause milder illness
than influenza A, but several studies have recently demon-
strated that infections with influenza A and B are clinically
indistinguishable and can cause severe complications in
both children and adults [1, 3–7]. Originally, influenza B
viruses represented a homogenous group but, since the late
1980s, they have evolved into two antigenically and genet-
ically distinct lineages, defined by the reference strains B/
Yamagata/16/88 (Yamagata lineage) and B/Victoria/2/87
(Victoria lineage) [8]. In the 1990s, Yamagata-like viruses
became predominant worldwide, whereas the Victoria
lineage was mainly restricted to East Asia. However, during
the 2000/2001 and 2001/2002 seasons, the Victoria-lineage
viruses re-emerged in North America and Europe and
spread globally [9, 10]. Since then, the two B lineages have
been co-circulating worldwide, with variability in terms of
geographic distribution and genomic evolution [10–12].
Vaccination is the most effective way to prevent influ-
enza virus infection and its complications. However, due
to the constant evolution of influenza viruses, seasonal
vaccines are regularly reformulated through continuous
global monitoring of the influenza viruses circulating in
humans, carried out by the National Influenza Centers
(NICs) and World Health Organization Collaborating
Centers (WHO-CC) within the WHO Global Influenza
Surveillance and Response System (GISRS). Currently,
the majority of influenza vaccines used worldwide are
trivalent formulations containing one representative
A(H1N1) virus, one A(H3N2) virus and only one B
strain (B/Victoria or B/Yamagata). The concurrent circu-
lation of the two B lineages over a lengthy period and
the limited or absent cross-reactive protection between
them have proven particularly challenging in terms of ef-
fectiveness of seasonal trivalent influenza vaccines (TIVs),
as demonstrated by the frequent lineage-level mismatches
occurring in the past between the predominant circulating
B viruses and the WHO-recommended B vaccine strain
[5, 13–16]. For this reason, quadrivalent influenza vac-
cines, containing viruses of both B lineages, have recently
been introduced in order to reduce the risk of occurrence
of B lineage vaccine mismatches [17, 18].
In this retrospective analysis, we provide an update on
the circulation of influenza B viruses over a 13-year
period (2004–2017) of surveillance in Italy, building
upon our previous reports and those at regional level
[19–23]. In particular, we document the molecular charac-
teristics of the hemagglutinin (HA) gene in the circulating
B strains over the 13 consecutive epidemic seasons and
the match between the dominant circulating B-lineage
and the lineage included in the TIVs in each season.
Methods
Influenza surveillance in Italy and retrospective data
collection
Influenza surveillance in Italy is based on a sentinel net-
work of physicians (InfluNet) who report the number of
patients with an influenza-like illness (ILI) on a weekly
basis and collect respiratory specimens from November
to April (i.e. from week 46 to week 17 of the following
year), for virological analyses. Each year, a variable pro-
portion of clinical specimens from non-sentinel sources
and hospitalized patients are also collected. Virological
surveillance is carried out by the NIC at the National In-
stitute of Health (Istituto Superiore di Sanità), in collab-
oration with the regional influenza laboratory network
(InfluNet). Preliminary analyses are performed on clin-
ical samples at regional level and a representative subset
of influenza virus-positive samples and/or virus isolates
is sent to the NIC and subsequently shared with the
WHO-CC for further antigenic and genetic analyses.
For this study, we analyzed all available virological data
on laboratory-confirmed influenza B clinical samples
collected within the framework of the InfluNet surveil-
lance system, from 2004/2005 to the 2016/2017 season.
To increase the number of specimens available for test-
ing, seven regional laboratories of the InfluNet network
(i.e. University laboratories of Milan, Trieste, Parma,
Perugia, Sassari, Florence and Bari) were involved in the
study and collaborated in the characterization analyses,
with particular regard to those samples collected during
the eight consecutive post-pandemic influenza seasons
(i.e. from 2009 to 2017). In accordance with applicable
laws and regulations, no clearance from an Ethics Com-
mittee is required in Italy for the retrospective analysis
of anonymized data collected within the routine influ-
enza surveillance scheme.
Laboratory testing and characterization analyses
Molecular characterization of the available clinical speci-
mens positive for influenza B virus and/or virus isolates
obtained in MDCK cells was performed following RNA
extraction, using the QIAamp Viral RNA extraction kit
(Qiagen, Hilden, Germany). A real-time RT-PCR assay,
recommended by the WHO, was used to discriminate
between influenza B lineages [24].
A subset of influenza B viruses (n = 491) underwent
genetic analysis using conventional Sanger sequencing
for the HA1 viral gene. Briefly, viral RNA was tran-
scribed to cDNA using random primers and the HA
gene was amplified with segment-specific primers for in-
fluenza B [25]. The PCR products were purified using a
PCR purification kit (Qiagen, Hilden, Germany) and
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sequenced using an ABI 3500 genetic analyzer (Applied
Biosystems, USA). Sequence alignment was performed
using the ClustalW method implemented in the BioEdit
program (v. 7.2.5). The phylogenetic trees were con-
structed using the Neighbor-Joining method and the
Kimura 2-parameter model, using MEGA software (v.
6.0). The HA sequences obtained in this study and used
in the phylogenetic analysis were entered in the EpiFlu
database of the Global Initiative on Sharing All Influenza
Data (GISAID) (see Additional file 1: Table S1).
Data analysis
For each season, we reported the number of samples
from ILI patients that were tested, the percentage of in-
fluenza positivity, and the number and percentage of
influenza-positive cases by viral type (A or B). Data on
the circulation of the two B lineages in the country were
obtained directly from this study or retrieved from the
seasonal influenza database. A lineage-level mismatch
between the WHO-recommended B component of the
TIVs for use in the northern hemisphere and the circu-
lating B viruses was defined as the percentage of influ-
enza B viruses belonging to a lineage different from that
included in the vaccine, for each season in Italy. A
complete mismatch was defined for the season when >
60% of circulating B viruses belonged to the lineage not
included in the TIV for that season.
For the age distribution and clinical presentation of
patients with confirmed B/Victoria and B/Yamagata in-
fections, median values and percentages were compared
using Mann-Whitney U tests and Chi-square tests, re-
spectively. The crude and adjusted relative risk (RR)
were estimated using the univariable and multivariable
log-binomial regression model. Analyses were performed
using STATA software v. 11.2 (Stata Corporation, Col-
lege Station, Texas, US).
Results
Circulating patterns of influenza A and B viruses in Italy
During the 13-year study period, a co-circulation of both
influenza A and B viruses was observed in Italy each year,
although in variable proportions and with a general pre-
dominance of type A over type B viruses (Fig. 1, Table 1).
Overall, type B viruses circulated on average four weeks
later than type A viruses, during winter months, with the
exception of three seasons (2010/2011, 2012/2013 and
2015/2016), when the epidemic peak of both influenza A
and B almost overlapped (Fig. 1). Across all seasons, 83,
479 respiratory specimens were collected and 26,886
(32.2%) of those samples tested positive for influenza vi-
ruses. Among these, 81.3% were type A viruses and 18.7%
type B viruses, with those percentage values being revised
to 76.7 and 23.3%, respectively, when adjusted for differ-
ences in total ILI incidence by season (Table 1). The num-
ber of influenza-positive samples per season ranged
between 307 in 2005/2006 and 3734 in 2014/2015. During
the 2009/2010 pandemic season, 6282 samples tested
positive for influenza, with the vast majority (> 99%) being
A(H1N1)pdm09. Estimated numbers of ILI cases were
also reported for each season in Italy (Table 1).
Fig. 1 Number of laboratory-confirmed influenza type A and B infections by season in Italy, during the study period (2004/2005–2016/2017).
Curves of the Influenza-like illness (ILI) incidence rate (× 1000 population served) are also shown for each epidemic season, by week
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Influenza B virus epidemiology and lineage
characterization
Influenza B virus detections predominated over type A
in only two seasons (2012/2013 and 2015/2016, B =
58%), and similar proportions of B viruses were detected
in the 2007/2008 season (B = 48%). Over the entire study
period, influenza B accounted for at least 20% of all
laboratory-confirmed influenza cases in six seasons
(Table 1). Approximately 59% (n = 2962/5028) of all la-
boratory-confirmed influenza B cases were from sentinel
sources (community-based infections), whereas the
remaining 35 and 6% were from hospitalized patients or
other non-sentinel sources, respectively (data not shown).
In this study, the lineage was characterized or retrieved
for 2465 (49%) out of 5028 laboratory-confirmed influ-
enza B infections (Table 2). Of these, B/Victoria and B/
Yamagata accounted for 53.3 and 46.7%, respectively. In
general, the co-circulation of the two lineages was
observed in all seasons considered in Italy, although in
different proportions and with alternating patterns, typ-
ically every two to three years. Nevertheless, an abrupt
annual switch in the predominant lineage occurred in
the most recent seasons included in the study, namely
2015/2016 and 2016/2017 (Fig. 2). In nine seasons, one
lineage predominated over the other, being identified in
> 80% of circulating B viruses, whereas a mixed circula-
tion was observed in the remaining four seasons (2004/
2005, 2006/2007, 2008/2009, 2011/2012). During the six
seasons with a higher circulation of B viruses (> 20% of
all laboratory-confirmed cases), B/Victoria was the
lineage most frequently detected in 2004/2005, 2005/
2006, 2010/2011 and 2015/2016, whereas B/Yamagata
lineage dominated in 2007/2008 and 2012/2013 (Fig. 2,
Table 2).
Comparison between the B lineage included in TIVs
and circulating B lineages in Italy in the seasons showed
that more than 50% (n = 1247/2465) of influenza B vi-
ruses belonged to the lineage not included in the sea-
sonal TIV (Table 2). A good match (89–98%) was
observed only in five seasons, whereas a complete mis-
match between the predominant influenza B lineage and
vaccine B lineage occurred in the other eight seasons
and, in particular, in four out of six seasons with intense
influenza B activity (2004/2005, 2005/2006, 2007/2008
and 2015/2016) (Fig. 2, Table 2).
Finally, laboratory-confirmed influenza B cases for
which age information for the patient was available were
stratified into five different age groups (Table 3). On the
whole, the groups most affected by influenza B were
children aged ≤14 years (64.5%) whereas the lowest pro-
portion was observed among subjects ≥64 years of age
(7.7%). When comparing the two lineages, patients in-
fected by B/Victoria viruses were significantly younger
than patients infected by B/Yamagata viruses (median
age: 7 years vs. 13 years; p < 0.001), with increased detec-
tion rates also observed in adults (see Additional file 2:
Fig. S1). In particular, the probability of infection with
B/Victoria viruses was twice as high in pediatric age
groups (0–4 years and 5–14 years) than in the elderly
(RR = 2.13 and RR = 2.27, respectively), and slightly
higher in hospitalized patients than in community-
reported cases (RR = 1.24) (Table 3).
Table 1 Number of samples tested and percentages attributable to influenza A and B virus types in Italy, as reported to the
virological surveillance system, by season (from 2004/2005 to 2016/2017)
Season Samples tested Influenza virus detections (%) N. of Influenza A viruses (%) N. of Influenza B viruses (%) Estimated ILI cases
2004/2005 3226 971 (30) 718 (74) 253 (26) 6336.000
2005/2006 2719 307 (11) 228 (74) 79 (26) 2347.000
2006/2007 1869 643 (34) 607 (94) 36 (6) 3675.000
2007/2008 1870 548 (29) 286 (52) 262 (48) 4692.000
2008/2009 2213 733 (33) 688 (94) 45 (6) 4105.000
2009/2010 16,433 6282 (38) 6230 (> 99) 52 (< 1) 5507.000
2010/2011 9193 2874 (31) 2082 (72) 792 (28) 5917.000
2011/2012 4677 1672 (36) 1610 (96) 62 (4) 5000.000
2012/2013 5535 2114 (38) 894 (42) 1220 (58) 6181.000
2013/2014 4426 1033 (23) 999 (97) 34 (3) 4542.000
2014/2015 10,299 3734 (36) 3133 (84) 601 (16) 6299.000
2015/2016 8985 2457 (27) 1044 (42) 1413 (58) 4877.000
2016/2017 12,034 3518 (29) 3339 (95) 179 (5) 5440.000
All seasons 83,479 26,886 (32.2) 21,858 (81.3)* 5028 (18.7)* 64,918.000
Influenza-like illness (ILI). Source: Influenza Sentinel Surveillance network (InfluNet);
*76.7 and 23.3%, when adjusted for differences in total ILI incidence by season
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Molecular and phylogenetic analysis of influenza B strains
The HA1 nucleotide sequences of influenza B viruses
(n = 812, 316 B/Victoria- and 496 B/Yamagata-lineage
strains) collected in Italy from 2004 to 2017 were ana-
lyzed. Among them, 491 (60.5%) were obtained in this
study and the remaining 321 were retrieved from the
GISAID and NCBI Influenza Virus Resource databases.
Figure 3 shows the phylogenetic relationship of HA1 nu-
cleotide sequences of 123 randomly selected influenza B
viruses (see also Additional file 1: Table S1) representing
the proportional distribution of different patterns of B/Ya-
magata (n = 75, Fig. 3a) and B/Victoria (n = 48, Fig. 3b) in
Italy. On average, for each season, the selected HA1 se-
quences showed more than 99.5% homology with those of
other B strains in the same genetic group, not included in
the final phylogenetic tree.
The B/Yamagata (Yam) strains were grouped into
three main genetic clades with the following reference
strains: Yam-1 (B/Florida/4/2006-like strain), Yam-2 (B/
Brisbane/3/2007- and B/Massachusetts/02/2012-like
strains) and Yam-3 (B/Bangladesh/3333/2007-, B/Wis-
consin/01/2010- and B/Phuket/3073/2013-like strains)
(Fig. 3a). In 2004/2005, one further small group was de-
tected, represented by the B/Jiangsu/10/2003 reference
strain, which included two Italian strains. The remaining
B Yamagata strains were characterized by a V251M sub-
stitution, relative to B/Shanghai/361/2002, which was
also found in the lone B/Yamagata strain analyzed in the
2005/2006 season. Among the higher proportion of B
detections reported during the 2007/2008 season (48%,
Table 1), B/Yamagata viruses largely predominated (81%)
over those of the B/Victoria lineage (Table 2) and were
grouped into the three clades. These were represented by
the reference strains B/Florida/4/2006 (Yam-1) (with the
G229S change also appearing in viral strains from 2006/
2007), B/Brisbane/3/2007 (Yam-2) (with the R48K and
Table 2 Proportion of infections caused by lineage-level mismatched influenza B viruses, compared with the vaccine strain, by
season (2004/2005–2016/2017) in Italy
Season Northern Hemisphere TIV B
lineage (strain)
N. of B viruses
characterized (%)
Prevalent B lineage in Italy
(virus variant)
N. of lineage-level mismatched vi-
ruses in Italy (%)
Seasonal
match (m)/
Mismatch (M)
2004/
2005*
Yam (Sha/361/02) 94 (37) Vic (Ill/13/05) 67 (71) M
2005/
2006*
Yam (Sha/361/02) 43 (54) Vic (Mal/2506/04) 36 (84) M
2006/
2007
Vic (Mal/2506/04) 17 (47) Yam (Flo/4/06) 13 (76) M
2007/
2008*
Vic (Mal/2506/04) 99 (38) Yam (Ban/3333/07) 80 (81) M
2008/
2009
Yam (Flo/4/06) 10 (22) Vic (Bri/60/08 +Mal/2506/
04)
7 (70) M
2009/
2010
Vic (Bri/60/08) 30 (58) Vic (Bri/60/08) 1 (3) m
2010/
2011*
Vic (Bri/60/08) 303 (38) Vic (Bri/60/08) 31 (10) m
2011/
2012
Vic (Bri/60/08) 37 (59) Yam (Wis/01/10) 24 (65) M
2012/
2013*
Yam (Wis/01/10) 488 (40) Yam (Mas/02/12) 21 (4) m
2013/
2014
Yam (Mas/02/12) 19 (56) Yam (Phu/3073/13) 2 (11) m
2014/
2015
Yam (Mas/02/12) 327 (54) Yam (Phu/3073/13) 6 (2) m
2015/
2016*
Yam (Phu/3073/13) 866 (61) Vic (Bri/60/08) 833 (96) M
2016/
2017
Vic (Bri/60/08) 132 (74) Yam (Phu/3073/13) 126 (96) M
All
seasons
2465 (49) 1247 (50.6)
Legenda: Yam: Yamagata; Vic: Victoria; Sha/361/02: B/Shanghai/361/2002; Mal/2506/04: B/Malaysia/2506/2004; Ill/13/05: B/Illinois/13/2005; Flo/4/06: B/Florida/4/
2006; Bri/60/08: B/Brisbane/60/2008; Wis/01/10: B/Wisconsin/01/2010; Mas/02/12: B/Massachusetts/02/2012; Phu/3073/13: B/Phuket/3073/2013
* Seasons with at least 20% of all influenza cases due to influenza type B viruses; Mismatch (M): > 60% of the characterized B viruses belonging to the lineage not
included in the seasonal TIV
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Fig. 2 Proportion of B/Victoria and B/Yamagata lineages among characterized influenza B viruses in Italy, by season (2004/2005–2016/2017). The
different color of the triangles (B/Victoria in orange; B/Yamagata in green) at the top of each bar represents the recommended influenza B
vaccine lineage. The red rectangle indicates a mismatch between the vaccine and the predominant influenza B lineage. Asterisks on the top of
the bars indicate the six seasons with a higher circulation of B viruses (> 20% of all laboratory-confirmed cases). The total number of influenza B
cases registered in Italy (lower line), along with the number of characterized influenza B viruses (upper line), for each season, are also shown on
the top of the graph
Table 3 Proportion of influenza B infections by age group and healthcare setting (Victoria vs Yamagata lineages)*, Italy 2004/2005–
2016/2017
Variables B/Victoria (N = 1267) B/Yamagata (N = 1097) RRcrude (95% CI) RRadj (95% CI) p-value**
n. (%) n. (%)
Median age (IQR) 7 (9) 13 (41) < 0.001***
Age group (years)
0–4 302 (23.8) 190 (17.3) 1.91 (1.53–2.39) 2.13 (1.70–2.67) < 0.001
5–14 655 (51.7) 380 (34.7) 1.97 (1.59–2.45) 2.27 (1.82–2.84) < 0.001
15–44 198 (15.7) 214 (19.5) 1.50 (1.19–1.90) 1.67 (1.31–2.12) < 0.001
45–64 54 (4.2) 190 (17.3) 0.69 (0.50–0.95) 0.72 (0.52–0.99) 0.047
> 64 58 (4.6) 123 (11.2) Ref – Ref – –
Healthcare settings
Community 927 (76.6) 810 (77.8) Ref – Ref – –
Hospitals 283 (23.4) 231 (22.2) 1.03 (0.94–1.13) 1.24 (1.15–1.35) < 0.001
*Crude and adjusted (adj) relative risk (RR) estimated using the univariable and multivariable log-binomial regression model with age bracket of > 64 as a
reference class;
CI: confidence interval
**p-value of the multivariable binomial negative model;
***p-value of the U Mann-Whitney test; p-values of < 0.05 were considered statistically significant
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P108A changes), and B/Bangladesh/3333/2007 (Yam-3)
(with the S150I, N165Y and G229D amino acid changes).
From the 2008/2009 to the 2010/2011 season, B/Yamagata
viruses circulated again at low levels and were grouped
mainly in the Yam-3 clade. In the subsequent 2011–2015
period, B/Yamagata viruses prevailed over B/Victoria vi-
ruses and were grouped into the Yam-2 and Yam-3 clades.
In particular, the 2012/2013 season was characterized by
an intense circulation of B viruses (58%, Table 1), largely
belonging to the Yam-2 clade (n = 158/174, 91%) related
more to the B/Massachusetts/02/2012 reference strain
and less to the Yam-3 clade, represented by the B/
Wisconsin/1/2010 vaccine strain. For this reason, B/
Massachusetts/02/2012 was included in the TIV for-
mulation for the subsequent 2013/2014 and 2014/
2015 seasons although those seasons were exclusively
dominated by the circulation of Yam-3 viruses, related
to B/Phuket/3073/2013, with N116K, K298E and
E312K changes compared to B/Wisconsin/1/2010. In
2015–2017, all the B/Yamagata viruses circulating in
Italy clustered with the 2015/2016 B/Phuket/3073/
2013 vaccine strain, with the additional L172Q and
M251 V amino acid changes. No further viruses be-
longing to the Yam-2 clade were observed in Italy fol-
lowing the 2012/2013 season.
The B/Victoria-like strains identified in Italy were
grouped with the following reference viruses that
emerged over time: B/Illinois/13/2005, B/Malaysia/2506/
2004 and B/Brisbane/60/2008. In particular, the HA
genes of the strains circulating in the 2005–2009 period
in Italy were closely related to the B/Malaysia/2506/2004
vaccine strain, sharing the K48E, K80R and K129 N
amino acid changes. Although circulating in very low
proportions over the whole season, most (66%) of the
2008/2009 B/Vic strains fell within a new clade (Vic-1),
represented by B/Brisbane/60/2008, with N75K, N165K
and S172P changes compared to B/Malaysia/2506/2004.
The following six seasons, from 2009/2010 to 2014/
2015, were characterized by the circulation of viruses be-
longing to Vic-1 clade, carrying the additional I146V
substitution compared to B/Brisbane/60/2008. Phylogen-
etic analysis shows that the Vic-1 clade is further divided
Fig. 3 Phylogenetic analysis of the HA1 nucleotide sequences from
influenza B/Yamagata (a) and B/Victoria (b) lineage viruses detected
in Italy between 2004 and 2017. Seventy-five HA1 sequences of B/
Yamagata (a) and 48 of B/Victoria (b) viruses were compared with
those from the WHO-recommended vaccine strains for the northern
hemisphere (in red, bold font) and other reference strains previously
reported by WHO-CC (in black, bold font). The strains identified in
Italy are colored according to their respective season, as illustrated in
the legend. The trees were constructed using the Neighbor-joining
method, with Kimura-2 parameter-corrected distances. Amino acid
substitutions defining specific genetic clusters are indicated at
nodes. The scale bar represents the nucleotide substitutions per site
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into 1A and 1B subclades, with Vic-1B viruses (B/Hong
Kong/514/2009-like strains) characterized by an L58P
amino acid change, as found in more than half (n = 44/
71; 62%) of the strains analyzed for 2010/2011. All the
remaining B/Victoria strains from 2010/2011 onwards
clustered differently with the B/Brisbane/60/2008 genetic
group (renamed Vic-1A) and those identified between
2015 and 2017 carried two additional amino acid
changes (I117V and N129D). The only exception was
represented by four B/Victoria strains from the 2015/
2016 season that were characterized by a different pat-
tern of mutations (i.e. I97M, K209 N and T258A), which
were more closely related to B strains circulating in pre-
vious seasons [23].
A comparison was made of the HA1 amino acid se-
quences of the Italian B viruses collected in the period
2012–2017 (145 Vic-1, 169 Yam-2 and 236 Yam-3) with
the respective vaccine strains within the four major epi-
tope domains comprising the 120-loop (position 116–
137), 150-loop (141–150), 160-loop (162–167), and the
190-helix (194–202) [26]. Among these, the 120-loop ap-
peared to be the most frequently mutated region in field
strains (Table 4) [27]. In particular, three substitutions
were detected more frequently within the 120-loop:
N116K (shared by 88.6% of Yam-3 viruses), I117V and
N129D (shared by 80.7 and 87.6% of Vic-1 viruses, re-
spectively). The I146V substitution was found in the
150-loop region of 13.8% of Vic-1 viruses, and mostly
identified in those strains circulating in the 2012/2013
and 2014/2015 seasons. Within the 190-helix, most Vic-
1 (97.9%), Yam-2 (100%) and Yam-3 (99.6%) viruses
acquired a potential glycosylation site with D197N/
D196N substitutions (based on Brisbane/60/2008- or
Massachusetts/02/2012- and Wisconsin/01/2010- vaccine
strain numbering) [26]. Moreover, the S202N substitution
was identified in 8.9% of Yam-3 viruses, and particularly
in those circulating from 2012 to 2015. Finally, additional
amino acid substitutions were found within the four anti-
genic epitopes and only detected in a few circulating field
strains (Table 4).
Discussion
Influenza B viruses represent a significant cause of re-
spiratory infections in humans that generally tend to
be overlooked because of the dominance of influenza
A [1, 3–5, 28]. In this study, we provide a comprehen-
sive picture of the circulation of the two influenza B
lineages in Italy, on the basis of 13 consecutive years
of national influenza surveillance data, from 2004/
2005 to 2016/2017. Overall, our data show that both
influenza type A and B viruses, and each lineage of in-
fluenza B, co-circulated annually in varying propor-
tions. Although influenza A viruses predominated in
the majority of the seasons considered, type B viruses
accounted for 20% or more of all influenza detections
in six seasons, playing a significant epidemic role in
the population. Moreover, we found that influenza B
was responsible for nearly 19% of all laboratory-
confirmed influenza cases, a figure thus comparable to
the global proportion (20%) reported by Caini et al.
during the period 2000–2013 in 26 countries around
the world, including Italy [29]. Influenza B virus detec-
tions exceeded those of influenza A in only two sea-
sons (2012/2013 and 2015/2016), with a switch in the
Table 4 Amino-acid substitutions found in the HA protein of 550 influenza B viruses (145 Victoria and 405 Yamagata) analyzed in
this study and detected in Italy during the period 2012–2017
Subunit Residue at site* Vic-1 (N = 145) Yam-2 (N = 169) Yam-3 (N = 236)
HA1 120-loop (116–137) I117V (117) R118K (1) N116K (209)
V124A (1) S120 T (7) N116R (5)
N129D (127) T121S (10) Q122K (9)
N123K (3) N123T (4)
D126N (3) D126N (1)
150-loop (141–150) I146V (20) G141R (1) S148 N (1)
T147A (1) S150I (1) I150V (1)
160-loop (162–167) N165Y (1)
D163N (1)
D163G (1)
190-helix (194–202) D197N (142) D196N (169) D196N (235)
N197D (3) T198N (1) D196Y (1)
T199A (2) N202S (2) K197R (4)
T199I (1) S202 N (21)
A202T (1)
*Amino acid substitutions reported in this table are compared with vaccine strains of respective clades and numbered according to respective vaccine strains (B/
Brisbane/60/2008 for Vic-1, B/Massachusetts/02/2012 for Yam-2, B/Wisconsin/01/2010 for Yam-3). The number of influenza viruses carrying the substitution is
indicated inside parenthesis
Puzelli et al. BMC Infectious Diseases          (2019) 19:990 Page 8 of 11
predominant B lineage. Indeed, a change in the rela-
tive predominance of the two influenza B lineages was
essentially observed every two/three years, with the
exception of the three more recent seasons, when a
lineage switch occurred each year, with a sudden shift
from B/Yamagata in 2014/2015 to B/Victoria in 2015/
2016 and back to B/Yamagata in 2016/2017. During
the study period, a good lineage-level match with the
WHO-recommended TIV B component was observed
in five seasons only, whereas the predominant lineage
differed in the remaining eight seasons, causing a
complete vaccine mismatch. In those seasons with
considerable influenza B activity, a mismatch was ob-
served in four seasons (2004/2005, 2005/2006, 2007/
2008 and 2015/2016). These results largely reflect
trends observed in other European countries, with the
exception of the 2004/2005 season, when the majority
of characterized B isolates in Europe belonged to the
Yamagata lineage [5, 30]. Overall, our data further
highlight the unpredictability of influenza B circula-
tion, which makes it challenging to predict which B
lineage will predominate in the upcoming influenza
season.
This study did not permit any vaccine effectiveness es-
timates related to the occurrence of B mismatches be-
cause of the limited availability of data on vaccination
status. However, the potential clinical impact of a B vac-
cine mismatch is mainly dependent on the proportion of
circulating influenza B viruses, as well as pre-seasonal
immunity in the population. Even though our analysis is
based on observational data only, we can assume that
the overall impact was minor in four out of eight seasons
with a complete B mismatch, given the very low propor-
tion of circulating influenza B viruses. For the other sea-
sons, a much higher impact can be expected, as
occurred in 2007/2008 when influenza B was found in
48% of the influenza positive samples in Italy and 81% of
the characterized B strains were vaccine-mismatched B/
Yamagata lineage viruses. Similarly, in 2015/2016, influ-
enza B was found in 58% of the influenza positive sam-
ples and 96% of the characterized viruses belonged to
the vaccine-mismatched B/Victoria lineage. Notably,
mismatched influenza B viruses were also reported in
seasons with a lineage-level vaccine match. In particular,
a high proportion (91%) of B/Yamagata strains circulat-
ing in Italy during the 2012/2013 season were related to
B/Massachusetts/02/2012-like (Yam-2 clade) strains, an-
tigenically distinguishable from the B/Wisconsin/1/2010
(Yam-3) vaccine strain. Interestingly, B/Yamagata lineage
viruses also predominated in the following two seasons
in Italy and worldwide, with a shift to clade 3 viruses,
closely related to the B/Phuket/3073/2013 strain and
differing from the B/Massachusetts/02/2012 vaccine
strain by at least 11 amino acid substitutions in the HA1
[12, 31–33]. Thus, an alternation of two antigenically
distinct B/Yamagata clades might have reduced the vac-
cine’s ability to protect against these viruses, although
they belong to the same lineage. Further studies are
needed to evaluate the extent of cross-reactivity between
influenza B viruses from distinct clades, and even from
different lineages, and thus establish the real impact on
vaccine effectiveness.
Phylogenetic analysis of influenza B viruses circulating
in Italy over the entire study period confirmed the co-
circulation of both lineages during each season, and re-
vealed a mixed circulation of distinct evolutionary viral
variants with different levels of match to the vaccine
strains. In particular, a gradual drift was observed in
both lineages and further clades and subclades were
identified in each lineage. However, following the 2012/
2013 season, B/Yamagata viruses of clade 3 dominated
in the influenza B virus population, thereafter showing
only limited amino acid variation. Similarly, the B/
Victoria lineage segregation into Vic-1A and Vic-1B sub-
clades was not detected further in Italy after the 2010/
2011 season and Vic-1A (B/Brisbane/60/2008-like) vi-
ruses became dominant, displaying only two important
amino acid substitutions in the antigenic 120-loop re-
gion of HA, as compared to B/Brisbane/60/2008 [34].
With regard to influenza B virus circulation among
the population in Italy, most influenza B infections (>
60%) were found in children aged ≤14 years, with the
highest proportion (nearly 44%) among school-age chil-
dren (5–14 years), in line with previous studies globally
[5, 15, 29, 35–37]. In particular, our study confirmed a
higher proportion of B/Victoria virus infections in chil-
dren than those caused by B/Yamagata viruses [38–42].
A similar distribution of B/Victoria and B/Yamagata
strains was observed in the community and in hospitals,
although there was a slightly higher probability of B/
Victoria infections in hospitalized patients. Indeed, pre-
vious studies have reported a greater proportion of B/
Yamagata virus infections in hospital inpatients across
two Italian regions [21]. The different time period and
number of patients with these characteristics may ac-
count for any difference observed in the outcomes for
the two studies. Furthermore, the potential association
between B lineage and age of infected patients and the
increased virulence of the B/Victoria lineage suggested
by others are still controversial and require further in-
vestigation [39, 40, 43–45].
There are some limitations in this study. Only laboratory-
confirmed influenza cases were included in the study, and
this could underestimate the real proportion of circulating
viruses and the true incidence of influenza infections in the
population. In addition, there were increased notifications
received by hospitals in later years, as a result of a much
higher demand for testing from the 2009 H1N1 influenza
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pandemic onwards. Lastly, we were only able to provide B
lineage information on almost half of all laboratory-
confirmed influenza B notifications. Nevertheless, we can
assume that these results would largely reflect the circula-
tion of the two influenza B lineages in Italy.
Conclusions
This study provides information on the viral evolution
and incidence of influenza B virus infections in Italy over
a 13-year period. Continuous co-circulation of both B
lineages highlights the complexity of antigenic variation
in influenza B viruses and the differences in the epi-
demiological profile of the target population. In addition,
the frequent occurrence of B-lineage mismatch with the
TIV, as observed during the 2004–2017 seasons, likely
contributed to the adoption of quadrivalent vaccines for
influenza vaccination programs in the country.
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